Orelabrutinib Combined With Lenalidomide and Immunochemotherapy for Relapsed/Refractory Primary Central Nervous System Lymphoma: A Retrospective Analysis of Case Series

BackgroundRelapsed/refractory (r/r) primary central nervous system lymphoma (PCNSL) is an intractable situation without sound treatment. Bruton’s tyrosine kinase (BTK) represents an attractive drug target in PCNSL. Orelabrutinib is a new-generation BTK inhibitor with high cerebrospinal fluid (CSF) c...

Full description

Bibliographic Details
Main Authors: Chuanwei Yang, Yong Cui, Xiaohui Ren, Ming Li, Kefu Yu, Shaoping Shen, Haihui Jiang, Mingxiao Li, Xiaokang Zhang, Xuzhe Zhao, Qinghui Zhu, Song Lin
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-06-01
Series:Frontiers in Oncology
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2022.901797/full

Similar Items